What is the recommended dose of clomipramine (tricyclic antidepressant) for Obsessive-Compulsive Disorder (OCD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Clomipramine for OCD

For adults with OCD, clomipramine should be initiated at 25 mg daily and gradually increased to 100 mg during the first 2 weeks, with further titration up to a maximum of 250 mg daily as needed for symptom control. 1

Initial Dosing and Titration

  • Treatment should begin with 25 mg daily and gradually increase to approximately 100 mg during the first 2 weeks 1
  • Initial doses should be given in divided doses with meals to reduce gastrointestinal side effects 1
  • After the initial 2 weeks, dosage may be increased gradually over several weeks up to a maximum of 250 mg daily 1
  • After titration, the total daily dose may be given once daily at bedtime to minimize daytime sedation 1

Pediatric Dosing (Children and Adolescents)

  • Starting dose is also 25 mg daily, gradually increased during the first 2 weeks 1
  • Maximum dose for children and adolescents is 3 mg/kg or 200 mg daily, whichever is smaller 1
  • As with adults, divided doses with meals are recommended initially, with transition to once-daily bedtime dosing after titration 1

Efficacy Considerations

  • Higher doses of clomipramine are associated with greater treatment efficacy for OCD compared to doses used for other conditions 2
  • Clomipramine was the first agent to show efficacy in OCD and some meta-analyses have suggested it may be more efficacious than SSRIs 2
  • However, head-to-head trials directly comparing clomipramine with SSRIs indicate equivalent efficacy 2
  • SSRIs have a higher safety and tolerability profile compared to clomipramine, which supports their use as first-line agents 2

Treatment Duration and Monitoring

  • An 8-12 week trial is considered optimal to determine efficacy 2
  • Significant improvement may be observed within the first 2-4 weeks of treatment 2, 3
  • Recommended maintenance duration after achieving remission is a minimum of 12-24 months 2
  • Longer treatment might be necessary due to risk of relapse after discontinuing medication 2

Safety Considerations and Adverse Effects

  • Most common adverse effects are anticholinergic (dry mouth, constipation) 3, 4
  • Other notable side effects include:
    • Nausea and gastrointestinal symptoms 3, 4
    • Sexual dysfunction 3
    • Sedation 1, 3
    • Potential for seizures at higher doses 3
  • Careful assessment of adverse effects is crucial when establishing the best dose for each patient 2
  • Clomipramine has a less favorable side effect profile compared to SSRIs, with higher withdrawal rates due to adverse effects (26% vs 11% for sertraline in comparative studies) 4

Treatment-Resistant Cases

  • For patients with inadequate response to SSRIs, clomipramine may be used as an augmentation strategy 2
  • In combination therapy with SSRIs, lower doses of clomipramine (25-50 mg) may be effective while minimizing adverse effects 5
  • Caution is needed when combining clomipramine with SSRIs due to risk of serotonin syndrome 2

Important Precautions

  • Allow at least 14 days between discontinuation of an MAOI and initiation of clomipramine 1
  • Steady-state plasma levels may not be achieved until 2-3 weeks after dosage change 1
  • Clomipramine requires careful monitoring due to its less favorable safety profile compared to SSRIs 2, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.

European psychiatry : the journal of the Association of European Psychiatrists, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.